JPMorgan Chase & Co. Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price cut by investment analysts at JPMorgan Chase & Co. from $120.00 to $74.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 243.95% from the company’s current price.

RARE has been the topic of several other reports. Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. HC Wainwright lowered their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Canaccord Genuity Group cut their price objective on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Leerink Partners lowered their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Finally, Guggenheim reduced their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a report on Monday, January 5th. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $65.76.

Ultragenyx Pharmaceutical Stock Performance

RARE traded down $0.70 on Thursday, reaching $21.52. The company had a trading volume of 750,029 shares, compared to its average volume of 2,463,697. The stock has a market cap of $2.08 billion, a P/E ratio of -3.69 and a beta of 0.16. The company’s fifty day moving average is $23.08 and its 200 day moving average is $28.93. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. During the same quarter in the prior year, the company earned ($1.39) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% compared to the same quarter last year. On average, sell-side analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

Insider Buying and Selling

In other news, CEO Emil D. Kakkis sold 54,404 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the completion of the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. This represents a 7.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John Richard Pinion sold 10,029 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $228,661.20. Following the completion of the transaction, the insider owned 110,026 shares in the company, valued at approximately $2,508,592.80. This trade represents a 8.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 104,958 shares of company stock valued at $2,394,858 over the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RARE. Flax Pond Capital LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $1,293,000. Caitong International Asset Management Co. Ltd raised its stake in Ultragenyx Pharmaceutical by 1,116,754.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 122,854 shares of the biopharmaceutical company’s stock valued at $2,826,000 after purchasing an additional 122,843 shares during the period. Alberta Investment Management Corp bought a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $883,000. Mercer Global Advisors Inc. ADV lifted its position in shares of Ultragenyx Pharmaceutical by 17.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 2,036 shares during the last quarter. Finally, Krensavage Asset Management LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter worth $3,442,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage gene‑therapy data showed improved control of ammonia levels in patients with a rare inherited disorder — a clinically meaningful result that supports the program’s value and potential commercial upside. Read More.
• Neutral Sentiment: Management gave investor presentations at the Leerink Global Healthcare and Barclays Global Healthcare conferences this week (transcripts available). These presentations recap pipeline strategy and commercial plans but did not contain new regulatory or financial milestones that would immediately change valuation. Read More. Read More.
• Negative Sentiment: Multiple law firms and shareholder‑alert services issued class‑action notices and lead‑plaintiff reminders tied to a securities lawsuit alleging investor harm (class period Aug 3, 2023–Dec 26, 2025). Firms named in notices include Pomerantz, Schall, DJS, Rosen, Faruqi & Faruqi, Levi & Korsinsky, Bronstein Gewirtz & Grossman, and others — one firm specifically flagged potential control‑person claims naming the CEO and CMO. The wave of filings/solicitations raises litigation overhang and potential settlement exposure, which is likely weighing on the stock. Read More.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.